Canaccord Genuity Keeps a Hold Rating on Endo International

By Austin Angelo

Canaccord Genuity analyst Dewey Steadman reiterated a Hold rating on Endo International (NASDAQ: ENDP) on November 12 and set a price target of $8. The company’s shares closed yesterday at $6.69, close to its 52-week low of $5.77.

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -5.6% and a 38.4% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Infotek Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Endo International is Hold and the average price target is $10, representing a 49.5% upside.

In a report issued on October 30, BMO Capital also reiterated a Hold rating on the stock with a $11 price target.

The company has a one-year high of $18.23 and a one-year low of $5.77. Currently, Endo International has an average volume of 6.6M.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENDP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S.